undamentalytics Newsletter
Sign in

Ultragenyx Pharmaceutical Inc. revenue

Ultragenyx Pharmaceutical Inc.'s revenue was $673m in fiscal 2025, up 20.2% on the year before. Since fiscal 2016 ($133,000) it has grown at a compound 158.0% a year. Over the last twelve months it was $717m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0351104271351363434560673717
Growth on the year before—+>999%+>999%+101.4%+161.3%+29.7%+3.4%+19.5%+29.0%+20.2%—
Gross profit—350————————
Gross margin—100.0%97.8%————————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $369M 54.8% ▲ 29.5%
Royalty $304M 45.2% ▲ 10.5%
Collaboration and License $0 0.0% —
Geography
Region Revenue Share YoY
North America $377M 56.0% ▲ 10.9%
Latin America $170M 25.3% ▲ 29.8%
EMEA $108M 16.0% ▲ 35.0%
Asia Pacific $18M 2.7% ▲ 100.0%

From Ultragenyx Pharmaceutical Inc.'s 10-K filed February 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Ultragenyx Pharmaceutical Inc. $717m 17.5% 21.2%
Nurix Therapeutics, Inc. $702m 738.8% 117.1%
Arrowhead Pharmaceuticals, Inc. $669m 16.8% 37.7%
TG Therapeutics, Inc. $800m 76.1% 221.5%
Telix Pharmaceuticals Ltd $804m 55.6% —
Ascendis Pharma A/s $814m 106.9% —

Compare with peers

Head to head: NRIX vs RAREARWR vs RARERARE vs TGTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ultragenyx Pharmaceutical Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ultragenyx Pharmaceutical Inc.